In the same period a year ago, the pharmaceutical developer posted earnings of $1.43 a share on sales of $3.2 billion.
The stock has fallen 0.4% since the company last reported earnings on Nov. 5.
Quarterly estimates have fallen 2.9 cents a share in the past month.
Mylan is currently trading at a price-to-forward-earnings ratio of 6.2 based on the 12-month estimates of 17 analysts surveyed by FactSet.
Jim Cramer and the AAP team are watching the pharmaceuticals sector. To find out more about what stocks they like in the industry click here now for more from Action Alerts PLUS.